Unity Biotechnology Inc (UBX) USD0.0001
Unity Biotechnology, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The Company is also developing systemic senolytic medicines using multiple modalities, including small molecules, antisense oligonucleotides and biologics. Its product portfolio includes UBX1325, UBX2050 and UBX2089. It targets cellular senescence and advancing senolytic programs in ophthalmologic and neurologic disorders. The Company also advancing other programs based on other biologies of aging, including an agonistic antibody to the Tie2 receptor to treat vascular eye disease and α-Klotho hormone to treat cognitive disorders.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.